Nestlé Purina Petcare Takes Category Management Strategy Into the Metaverse With Blue Yonder and 3DVR Solutions
24.1.2023 16:00:00 EET | Business Wire | Press release
To improve customer experience and satisfaction, retailers are looking to offer a personalized assortment and easy to navigate display of products in their stores. That’s why Nestlé Purina Petcare, the leading manufacturer of pet care products, has successfully implemented Blue Yonder’s category management solution integrated with 3DVR Solutions’ (3DVRS) 3D virtual reality technology to assist its retail partners with better merchandizing of their store shelfs.
Purina is the No. 1 pet care company in the U.S. It offers more than 20 brands in the U.S., feeding 65 million dogs and 51 million cats annually. Purina provides its retail partners with planograms that design shelfs aimed at merchandizing products to meet customer needs. However, with travel restricted during the COVID-19 lockdowns, it needed an alternate way for its associates to work with its retail partners remotely to replicate critical tasks that would otherwise be performed in front of a physical planogram or in store.
Enter 3DVRS’ innovative Retail Visualisation Suite (RVS) Virtual Reality (VR) Headset solution, which combines planogram data from Blue Yonder with a cutting-edge virtual reality headset provider to deliver a fully interactive, networked avatar-based merchandising solution. This integrated solution brings people from all over the globe into a common unique headset experience in the metaverse where they can plan, present and interact. The integrated solution is now also available to other companies who are looking to solve similar challenges.
Thanks to this integrated solution, Purina has achieved some key benefits:
- Removed the need to be in a physical store to make shelfing decisions by bringing people together in the metaverse, which has in turn reduced environmental impact from less travel and decreased training costs.
- Reduced time to merchandise a shelf via an interactive planogram before moving real product.
- Incorporated true-to-life factors into shelf planning.
- Partner with retailers to enhance the customer journey in store and share global best practices.
“3DVRS’ integration with Blue Yonder delivers flexibility, speed and scale, giving us the ability to effectively deploy across the business. The evolution from virtual reality on the desktop to network avatars in the RVS VR Headset solution has been seamless. We can now hold meetings virtually in the metaverse, interact with layouts, products, and store innovations, allowing us to be right at the cutting edge,” said Gene Feldman, training manager, Purina.
Together, Blue Yonder's category management and 3DVRS’ RVS VR Headset solutions have enabled Purina’s retail partners to make faster, more accurate and localized space allocation decisions to help their customers find the products they need more easily while guaranteeing a better shopping and service experience.
“Purina is a fantastic partner to innovate with as they are always looking to the latest technology to give their business the edge. The challenges they presented pushed technological boundaries. Our integration with Blue Yonder gives us the platform to support large enterprises such as Purina. It’s great to bring new tech to the market that makes a real difference. It’s amazing what we have achieved together already, but I sense there's a lot more to come,” said Nigel Hemer, CEO and founder, 3DVR Solutions.
“Working with 3DVRS has allowed us to bring Blue Yonder’s planograms to life in the metaverse where users can merchandise, analyze, interact, and meet as avatars to design shelfs that meet customers’ needs. This is cutting-edge technology at its finest and Purina was one of the first companies to benefit from it. By creating a culture of innovation and thought leadership throughout the organization, Purina is building a great place to work for both their associates and retail partners,” said Phillip Teschemacher, corporate vice president, Manufacturing - EMEA, Blue Yonder.
Additional Resources:
- Learn more about Blue Yonder's category management solution
- Learn how to achieve smarter Category Management with Blue Yonder
About Nestlé Purina PetCare
Nestlé Purina PetCare creates richer lives for pets and the people who love them. Founded in 1894, Purina has helped dogs and cats live longer, healthier lives by offering scientifically based nutritional innovations.
Purina manufactures some of the world's most trusted and popular pet care products, including Purina Cat Chow, Purina ONE, Pro Plan, Fancy Feast and Tidy Cats. Our more than 8,700 U.S. associates take pride in our trusted pet food, treat and litter brands that feed 51 million dogs and 65 million cats every year. More than 500 Purina scientists, veterinarians, and pet care experts ensure our commitment to unsurpassed quality and nutrition. Purina promotes responsible pet care through our scientific research, our products and our support for pet-related organizations.
Over the past five years, Purina has contributed more than $150 million towards organizations that bring, and keep, people and pets together, as well as those that help our communities and environment thrive. Purina is part of Nestlé, a global leader in Nutrition, Health and Wellness. For more information, visit purina.com or subscribe here to get the latest Purina news.
About 3DVR Solutions
As a global Blue Yonder technology partner for 10 years, 3DVRS leverages Blue Yonder planogram and store CAD data to create highly visual 3D environments, enabling retailers & suppliers to plan, design and respond to rapidly changing market conditions. The unique design of 3DVR’s virtual reality solutions deliver automation, speed and scale without inherent dependencies and costs. 3DVR support Blue Yonder customers around the globe, including those on Microsoft Azure. www.3dvrs.com
About Blue Yonder
Blue Yonder is the world leader in digital supply chain transformations and omni-channel commerce fulfillment. Our end-to-end, cognitive business platform enables retailers, manufacturers and logistics providers to best fulfill customer demand from planning through delivery. With Blue Yonder, you'll unify your data, supply chain and retail commerce operations to unlock new business opportunities and drive automation, control and orchestration to enable more profitable, sustainable business decisions. Blue Yonder - Fulfill your Potential™ blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005378/en/
Contact information
Blue Yonder Public Relations Contacts:
Marina Renneke, APR, Corporate Communications Director
Tel: +1 480-308-3037, marina.renneke@blueyonder.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
